Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma

Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous squamous cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical RAS/RAF/MAPK pathway activation. Here we identify frequent TGFBR1 and TGFBR2 mutations in human vemurafenib-induced skin lesions and in spora...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: Cammareri, Patrizia, Rose, Aidan M., Vincent, David F., Wang, Jun, Nagano, Ai, Libertini, Silvana, Ridgway, Rachel A., Athineos, Dimitris, Coates, Philip J., McHugh, Angela, Pourreyron, Celine, Dayal, Jasbani H. S., Larsson, Jonas, Weidlich, Simone, Spender, Lindsay C., Sapkota, Gopal P., Purdie, Karin J., Proby, Charlotte M., Harwood, Catherine A., Leigh, Irene M., Clevers, Hans, Barker, Nick, Karlsson, Stefan, Pritchard, Catrin, Marais, Richard, Chelala, Claude, South, Andrew P., Sansom, Owen J., Inman, Gareth J.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007296/
https://ncbi.nlm.nih.gov/pubmed/27558455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12493
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares